Project description DEENESFRITPL New regenerative implant to prevent total knee replacement Knee cartilage deterioration or injuries are often the cause of osteoarthritis. This chronic disease associated with pain, stiffness and severe disability decreases the quality of life and represents a serious economic burden for health systems. However, existing treatments such as total knee joint replacement are expensive and often involve complications. The EU-funded FibroFix Cartilage project proposes a regenerative orthopaedic implant that addresses the problem of large and/or osteoarthritic articular cartilage lesions in the knee. The silk-based implant is biostable and biocompatible, emulating cartilage function and supporting cartilage regeneration at a significantly lower cost than other solutions. The product allows prolonged use of the joint, increases mobility, reduces pain and postpones or prevents total knee replacement. Show the project objective Hide the project objective Objective FibroFix™ Cartilage, silk-based implant for cartilage repair and regeneration, introducing a new paradigm in osteoarthritis treatment.Cartilage deterioration and injuries often lead to osteoarthritis (OA) – a long-term chronic disease resulting in bones rubbing together and creating pain, stiffness and severe disability. Knee cartilage injuries are very common and almost half of them go on to develop OA, which is second only to heart disease as a cause of work disability. Resulting from decreased qualityof life, hospitalizations and loss of productivity, the economic cost of OA is particularly high in every country that it has been estimated. Currently, all treatments available, including Total Knee joint Replacement (TKR) as the ultimate recourse, are inefficient and expensive: they involve pain, lengthy rehabilitation, frequent complications and high costs. Therefore, giventhe increasing prevalence of knee OA, its associated burdens and the drawbacks of all available treatments, it is becoming increasingly important to develop an innovative cost-effective solution to this major public health problem worldwide.FibroFix™ Cartilage is a well characterised, regenerative orthopaedic repair product to address the unmet and pressing clinical need of large and/or osteoarthritic articular cartilage lesions in the knee, developed by Orthox. It is biostable, biocompatible, emulates cartilage function and supports cartilage regeneration at the minimum cost effectiveness ratio. It allows resurfacing of large and/or potentially OA cartilage lesions, prolonged use of the joint, increased mobility, reduced pain and postponement or prevention of TKR. Smooth, robust, resilient, durable and lubricious, it is a unique combination to be applied in orthopaedics and biomaterials shifting the paradigm in knee OA treatment and up to 10 times less expensive than other solutions. Fields of science medical and health scienceshealth sciencespublic healthmedical and health sciencesclinical medicinephysiotherapymedical and health sciencesclinical medicineorthopaedicsengineering and technologyindustrial biotechnologybiomaterialsmedical and health sciencesmedical biotechnologyimplants Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-EIC-SMEInst-2018-2020-3 Funding Scheme SME-2b - SME Instrument (grant only and blended finance) Coordinator ORTHOX LIMITED Net EU contribution € 2 496 960,38 Address 66 innovation drive milton park OX14 4RQ Abingdon United Kingdom See on map Region South East (England) Berkshire, Buckinghamshire and Oxfordshire Oxfordshire Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 1 070 125,87
